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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease involving the synovial joints, which is medi-
ated by various cytokines including interleukin-1β
(IL-1β) and tumor necrosis factor-α (TNF-α).1–4
Etanercept (Enbrel; Wyeth Pharmaceuticals, Mon-
mouth Junction, NJ, USA) is a chimeric protein com-
prised of a 75-kDa soluble tumor necrosis factor
(TNF) receptor (sTNFR) and the Fc portion of
immunoglobulin G1 (IgG1Fc), which can competi-
tively inhibit the interaction between TNF-α and its
corresponding cell-surface receptor, thus preventing
the active inflammatory process in the rheumatoid
synovium.5
The efficacy and safety of etanercept twice weekly
subcutaneous injection have been demonstrated by
previous clinical investigations, which showed re-
markable pain relief associated with improvement in
joint destruction as well as negligible side effects.6,7
These beneficial effects usually occur within 6 months
after the start of treatment. Prevention of progression
of the inflammatory process has also been demon-
strated.8 Nevertheless, occurrences of side effects such
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as injection site reaction, demyelinating disease, ag-
gravation of congestive heart failure, or activation of
tuberculosis (TB) have been infrequently reported.5,9–11
Etanercept was first launched in Taiwan in early
2004. Since then, Taipei Veterans General Hospital
(VGH) has been one of several hospitals in Taiwan
that has had the opportunity to treat RA patients sys-
tematically with this agent. Herein, we present our
experience with this agent in treating active and/or
debilitating RA patients in this hospital, which is the
first systematic post-marketing report in Taiwan.
Methods
From January 2004 to June 2007, a total of 133
patients with active RA were entitled to receive etan-
ercept (25 mg subcutaneous injection, twice a week)
in Taipei VGH by the health administrator, the
Bureau of National Health Insurance (BNHI), Taiwan.
The enrolment criteria included age of at least 18
years, fulfillment of the 1987 American College of
Rheumatology criteria for the diagnosis of RA,12 an
active disease as defined by disease activity score in 28
swollen and 28 tender joints (DAS28) of more than
5.1 points,13,14 and failure to respond to combination
therapy with at least 2 disease-modifying antirheumatic
drugs (DMARDs) for more than 6 months. These
DMARDs included the requisite oral methotrexate
(15 mg/week) and ≥ 1 additional compounds such as
hydroxychloroquine (200mg twice a day), sulfasalazine
(2 g/day), cyclosporine A (100 mg/day) or lefluno-
mide (20 mg/day). Patients were excluded if they had
malignancy, were pregnant, or were at high risk of
infection (such as those with chronic skin ulceration,
a previous TB infection, septic arthritis within 12
months, infected joint prosthesis, refractory lung
infection or those using an indwelling catheter in the
urinary tract). After DMARD failure was verified by
the BNHI, individual patients received a 3-month
course of etanercept injection; they continued the
injections if clinical benefit was achieved and if they
had obtained a permit from the BNHI for another 
3-month course.
Along with etanercept, all patients continued their
previous combination regimen including the requisite
methotrexate and ≥ 1 DMARDs. Oral corticosteroids
(methylprednisolone or prednisolone) and nonsteroidal
anti-inflammatory drugs (NSAIDs) were provided as
usual, but patients could reduce the doses at will if
pain improved.
We analyzed patients’ erythrocyte sedimentation rate
(ESR) by the Westergren method, serum rheumatoid
factors (RFs) and C-reactive protein (CRP) level by
nephelometric analysis, and recorded their DAS28
score every 3 months from the start of the treatment
protocol. In counting DAS28, tender joint count
(TJC) and swollen joint count (SJC) were also recorded.
These 2 parameters were considered as additional de-
pendent variables and were separately plotted against
time course. Some of the patients exited out of the
treatment protocol because of medical or non-medical
reasons. If the patients agreed, serum was also collected
for detection of antibodies against cyclic citrullinated
peptide (anti-CCP) using a commercially available
ELISA kit (Diastat; Axis Shield Diagnostics, Dundee,
UK) as described previously,15 at the beginning and
end of the 6th month of etanercept therapy.
All patients were evaluated for the safety of etaner-
cept treatment every 3 months after the start. Stan-
dard laboratory measurements were performed by the
affiliated central laboratory and comprised hematol-
ogy (complete blood cell and differential counts), serum
biochemistry (creatinine, blood urea nitrogen, alanine
transaminase, aspartate transaminase, total protein and
albumin), and urinalysis. Every patient underwent plain
posteroanterior chest radiographic examination before
the start of the biologics. If cardiopulmonary diseases
were suspected at any time during the treatment pro-
tocol, then chest X-ray examinations were performed
again. Other manifestations such as injection reac-
tion, skin rash, dyspnea, neoplasm, infection episodes
or development of other autoimmune diseases, if they
occurred, were also recorded.
Statistical analysis
Data are presented as mean ± standard error of 
the mean. Statistical significance was calculated by
nonparametric Wilcoxon’s signed ranks test using
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) for
Windows. A p value < 0.05 was taken to indicate 
significant difference.
Results
As shown in Table 1, in this VGH etanercept cohort,
the mean age was 49.7 ± 0.3 years, with a female-to-
male ratio of 5.3:1. Mean disease duration from the
onset of symptoms was 0.5–15 years, and the mean
number of previously prescribed DMARDs was
2.9 ±1.3 (range, 2–5). All enrolled patients took oral
methotrexate (15 mg weekly) as a prerequisite before
the start of etanercept, and 90% of them also took
hydroxychloroquine (400 mg daily). The average
DAS28 was 6.98 ± 1.02 at the start of biologics, 
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ESR was 55.61 ± 30.25 mm/hr, and CRP was 4.10 ±
0.39 mg/dL. The whole duration of observation was
12 months, during which there were 39 patients who
had their etanercept treatment prematurely terminated
by the BNHI because of administrative reasons
(n = 34), ineffectiveness (as defined by BNHI, n = 5),
and/or the appearance of adverse effects. There was
no voluntary withdrawal due to adverse effects or
aggravation of joint inflammation. The remaining 94
patients completed the entire study protocol at 12
months. There were 10 patients who intended to con-
tinue etanercept injection after 12 months because of
the conspicuous treatment effect. These additional treat-
ments were not covered by BNHI and were waived of
insurance payment (data not shown).
A total of 94 patients completed the 1-year course
of etanercept injection. As shown in Figure 1A, the
mean DAS28 score was 6.98 ± 1.02 at the beginning of
treatment, 3.99 ± 1.46 at the end of 3 months of treat-
ment, 3.30 ± 1.17 at the end of 6 months of treat-
ment, 2.65 ± 0.90 at the end of 9 months of treatment,
and 2.46 ± 0.88 at the end of 1 year of treatment.
After 3 months of treatment, almost all patients had
achieved significant improvement in symptoms and
signs, with a significant reduction in DAS28 score
accompanied by parallel falls in ESR.
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Table 1. Demographic features and medications in 133 patients
receiving etanercept therapy
Mean age (yr) 49.7 ± 2.3
Sex (female/male) 112/21
Disease duration from onset (yr) 0.5–15
Positivity of rheumatoid factors, n (%) 130 (97.8)
Mean number of prior DMARDs 2.9 ± 1.3
Prior methotrexate use (%) 100
Prior and concomitant corticosteroid use (%) 68
Prior and concomitant 90
hydroxychloroquine use (%)
Prior and concomitant NSAID use (%) 100
% reducing or stopping 16.7
NSAID after start of etanercept
DMARDs = disease-modifying antirheumatic drugs, including methotrexate
(15 mg weekly), hydroxychloroquine (400 mg daily), sulfasalazine (2 g/day),
cyclosporine A (2.5 mg/kg/day) and leflunomide (20 mg daily); NSAID = non-
steroidal anti-inflammatory drug.
10
8
6
4
2
0
0
Months after treatment
D
A
S2
8
3 6 9 12
p < 0.0001
A
20
15
10
5
0
0
Months after treatment
Sw
ol
le
n 
jo
in
t 
co
un
t
3 6 9 12
C
30
25
20
15
10
5
0
0
Months after treatment
Te
nd
er
 jo
in
t 
co
un
t
3 6 9 12
p < 0.001
B
p < 0.001
Figure 1. Changes in: (A) DAS28 score, (B) tender joint count,
and (C) swollen joint count during the 1-year treatment period.
Data are presented as mean ± standard error of the mean.
Comparisons were made between the data at the beginning of
treatment and those at 3 months; p < 0.001 as calculated by
Mann-Whitney U test.
As shown in Figure 2A, mean ESR was 55.61 ±
30.25 mm/hr at the beginning of treatment, 25.07 ±
23.57 mm/hr at the end of 3 months of treatment,
22.97 ± 19.87 mm/hr at the end of 6 months of treat-
ment, 19.66 ± 13.37 mm/hr at the end of 9 months of
treatment, and 17.95 ± 12.50 mm/hr at the end of 
1 year of treatment. Serum CRP levels showed a sim-
ilar trend. As shown in Figure 2B, mean CRP was
4.10 ± 0.39 mg/dL at the beginning of treatment,
1.61 ± 0.27 mg/dL at the end of 3 months of treat-
ment, 1.37 ± 0.22 mg/dL at the end of 6 months of
treatment, 1.02 ± 0.20 mg/dL at the end of 9 months
of treatment, and 0.73 ± 0.17 mg/dL at the end of 
1 year of treatment. TJC and SJC were also signifi-
cantly reduced. As shown in Figure 1B, mean TJC
was 17.3 ± 8.3 at the beginning of treatment, 5.1 ± 4.7
at the end of 3 months of treatment, 2.7 ± 2.7 at the
end of 6 months of treatment, 1.7 ± 2.2 at the end of
9 months of treatment, and 1.2 ± 1.5 at the end of 
1 year of treatment. Mean SJC was 11.0 ± 7.2 at the
beginning of treatment, 2.4 ± 2.8 at the end of 3
months of treatment, 1.6 ± 3.7 at the end of 6 months
of treatment, 0.6 ± 1.3 at the end of 9 months of treat-
ment, and 0.4 ± 1.0 at the end of 1 year of treatment
(Figure 1C). Some patients (n = 21, data not shown)
even attained a remission status as defined by DAS28
score < 2.6.16 Actually, improvement in inflammation
could be seen as early as 1 week after the beginning of
treatment, as evidenced by the observation that the
doses of oral glucocorticoids and NSAIDs were re-
duced by some patients themselves when the 3rd
doses of etanercept were given. As shown in Figures 1
and 2, the effect on improvement in all parameters
became stabilized after 3 months of treatment, and
there was no evidence of recurrence or aggravation of
inflammation in the late period of the therapeutic
program. Clinical response might have been sustained
beyond 1 year in some patients (n = 26) whose treat-
ments were not arbitrarily terminated by the BNHI.
Among 39 patients who departed out of the proto-
col, 17 could be followed-up regularly after stopping
etanercept. As shown in Figure 3, the average DAS28
scores were 6.42 ± 1.38 before the patients received
etanercept therapy (baseline), 3.74 ± 1.20 at the end
of etanercept therapy (0 month), and 3.14 ± 1.16,
2.92 ± 1.94, 4.19 ± 2.74 and 4.76 ± 2.27 at 3, 6, 9
and 12 months, respectively, after stopping biologics.
The average DAS28 score might be sustained at a low
level for a period of approximately 6 months in the
presence of continuous DMARD therapy, but the dis-
ease activity began to return afterwards, suggesting a
prolonged effect of etanercept.
Serum IgG, IgA, and IgM levels were not followed-
up in every patient, but the available data indicated
that these parameters remained stable during the treat-
ment periods (data not shown). However, serum RFs
declined remarkably in some patients (from 539.20 ±
200.15 IU/mL to 284.90 ± 122.08 IU/mL, n = 20)
during the initial 6 months. Serum anti-CCP antibod-
ies showed a decreasing trend in 6 patients (from
261.33 ± 145.97 U/mL to 96.67 ± 55.51 U/mL) dur-
ing the first 6 months of treatment.
Of the patients who completed the treatment sched-
ule (n = 94), serious treatment-related adverse effects
were rarely observed throughout the whole year
except in 3 patients who left the protocol because of
medical reasons including development of leukemia,
lymphoma and ovarian cancer. None of the patients
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Figure 2. Changes in: (A) erythrocyte sedimentation rate (ESR), and (B) C-reactive protein (CRP) during the 1-year treatment period. ESR
was measured by the Westergren method at 1 hour. CRP was measured by nephelometry. A total of 94 patients completed the 1-year
course of etanercept injections. Data are represented as mean ± standard error of the mean. Comparisons were made between the
data at the beginning of treatment and those at 3 months; p < 0.001 as calculated by Mann-Whitney U test.
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stopped treatment because of subjectively feeling inef-
fectiveness or reluctance to therapies on their own. One
patient developed leukemia before the etanercept ther-
apy. After a confirmative diagnosis was made, etaner-
cept injection was immediately stopped at the 7th
month. However, he still died of leukemia several
months later. Another patient with long-standing RA
was found to have ovarian cancer in the 10th month
of the biologic therapy. There was no overwhelming
evidence to show that etanercept injection was rele-
vant to the development of her tumor. As shown in
Table 2, injection site reaction was a frequent adverse
effect, including skin rash (n = 7) and pruritus (n = 9).
Common cold was the most common infection event
(n = 9). Other infection episodes included cellulitis
(n = 2), pneumonia (n = 1, pathogenic microorganism
not actually identified), shingles (n = 2), and renal
abscess (n = 1, pathogenic microorganism not actually
identified). The causative pathogens for cellulitis were
not actually identified, but the infectious episodes in
those 2 patients were well treated with intravenous
ampicillin. There was no definitely confirmed TB devel-
opment. One patient who was suspected to have pul-
monary TB was diagnosed by mycobacterial polymerase
chain reaction rather than microorganism isolation
and identification. Etanercept treatment was stopped
immediately after the PCR diagnosis and the patient
received an empirical course of prophylactic treat-
ment. The patient did not resume etanercept therapy
subsequently. The compliance of patients was gener-
ally good except that 36 patients were forced to leave
the treatment protocol by the BNHI. The reasons for
suspension of treatment included migration of resi-
dence, termination of reimbursement, or randomized
cessation of treatment protocol selected by the BNHI.
Discussion
Enhanced TNF-α activity plays an important role in
inflammatory arthritides, including RA.1–4,17,18 Etaner-
cept blocks the interaction between TNF-α and
TNFR on the cell surface, thus preventing further
synovial inflammation.19,20 This 1-year open-label post-
marketing study showed the efficacy of etanercept on
RA patients who had failed the traditional combina-
tion therapy with DMARDs, adding more evidence
to support the efficacy of etanercept in RA treatment.
A significant improvement was noted in both labora-
tory parameters (CRP, ESR, anti-CCP antibody, RFs)
and clinical parameters (DAS28, TJC, SJC).
After the emergence of biologics as the mainstay
of treatment for RA as well as other autoimmune dis-
eases, accumulating reports of increased infections in
patients undergoing anti-TNF-α therapy became a
great concern because of potential interruption of the
normal inflammatory process by these cytokine or
cytokine receptor inhibitors.21–26 In our present etan-
ercept cohort, 6 patients were hospitalized due to infec-
tious episodes, not necessarily relevant to the biologic
Table 2. Adverse events reported by the patients or recognized
by the physicians during etanercept therapy
Adverse event n F:M
Skin rash other than at injection sites 7 4:3
Pruritus with or without 9 6:3
rash at injection sites
Lymphoma 1 0:1
Congestive heart failure 2 2:0
Elevation of alanine/ 3 1:2
aspartate transaminase
Headache 1 1:0
Dyspepsia 1 1:0
Cellulitis 2 1:1
Pneumonia 1 1:0
Shingles (Varicella zoster) 2 1:1
Common cold 12 9:3
Newly developed hypertension 1 1:0
Leukemia* 1 0:1
Ovarian cancer 1 1:0
Renal abscess 1 1:0
Pulmonary tuberculosis (suspected) 1 1:0
Death* 1 0:1
*The same patient who was found to have leukemia during etanercept treat-
ment, which was then stopped, died eventually of septic shock.
Figure 3. Follow-up of DAS28 in 17 patients who left the treat-
ment protocol but who were still on regular medications with 
disease-modifying antirheumatic drugs. There was a tendency for
disease activity to steadily decrease 3–6 months after stopping
the biologics, but then begin to climb up again afterwards.
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therapy itself. These included cellulitis (n = 2), shingles
(n = 2), pneumonia (n = 1), and renal abscess (n = 1).
The only case receiving prophylactic antituberculous
treatment did not show definite tissue proof of my-
cobacterial infection. All patients recovered success-
fully from microbial infections after adequate antibiotic
treatment. Because all of the patients were concomi-
tantly under oral methotrexate treatment, it was likely
that methotrexate alone, or in addition to etanercept,
rendered these patients increasingly susceptible to 
opportunistic infections. Indeed, among RA patients in
this hospital who underwent combination therapy with
methotrexate, hydroxychloroquine, and sulfasalazine
but not etanercept also suffered from increased chance
of getting opportunistic infections (data not shown).
Because there was no patient who was treated with
etanercept alone throughout the whole course, it is
not known whether etanercept can really be impli-
cated in the increased incidence of opportunistic
infections, although early trials of etanercept by other
authors have revealed that increased incidence of neu-
tropenia as well as infections might occur in patients
undergoing either etanercept treatment or methotrex-
ate treatment.27 In the patient who suffered from
bacterial pneumonia, the causative pathogen was not
identified. However, the pulmonary infection was com-
pletely controlled by empirical antibiotic therapy with
cefuroxime. A polymerase chain reaction for Mycobac-
terium tuberculosis as well as acid-fast stain of the con-
centrated sputum smear had excluded the possibility
of TB. In contrast to those reported by other authors
who showed increased risk of TB infections in patients
undergoing infliximab, etanercept, or adalimumab,28–30
we did not find increased risk of TB in our etanercept
cohort. A possible cause of this might be the strict
entry criteria for etanercept therapy, excluding all the
patients who were previously suspected to have active
or healed typical or atypical mycobacterial infections.
According to the treatment protocol set up by BNHI,
we were not permitted to treat patients only with
etanercept. Thus, it is difficult to infer that these spo-
radic infection episodes were directly relevant to the
etanercept injection.
Another interesting point demonstrated in the
present investigation was that 17 patients who had
their etanercept treatment prematurely terminated
were followed-up for an additional 6 months, during
which the disease activity seemed to be kept low
despite the absence of biologic therapy (Figure 3).
The beneficial effect of antecedent etanercept injec-
tion seemed to be sustained for about 6 months in
the presence of continuous DMARD administration.
This finding has not been reported before, although
previous investigations have demonstrated that etan-
ercept together with methotrexate could exert a more
beneficial effect and achieve sustained remission of
rheumatoid activity than methotrexate alone.31,32 This
is interesting and inspiring because it suggests that
blockade of TNF-α activity might be maintained at
least for a substantial period in the presence of other
DMARDs in active rheumatoid synovium. The effec-
tiveness of etanercept was also reflected by the good
compliance of our patients, with only sporadic cases
having their injections stopped prematurely due to
non-medical reasons. The benefits as well as draw-
backs of etanercept as monotherapy for RA deserve
future investigations.
In conclusion, a post-marketing investigation of
etanercept in a teaching hospital in northern Taiwan
has revealed that etanercept combined with methotrex-
ate, hydroxychloroquine, sulfasalazine, cyclosporine
or leflunomide is generally safe, well tolerated and effec-
tive in patients with active RA in whom traditional
DMARD treatment has failed.
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